Innate Pharma (IPHYF) News Today $1.45 0.00 (0.00%) As of 04/24/2025 Add Compare Share Share Headlines Stock AnalysisChartHeadlinesSEC FilingsShort InterestBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Innate Pharma announces EUR 15M capital increase from SanofiApril 24 at 5:35 PM | markets.businessinsider.comInnate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi’s Intention to Make a Strategic Investment in the CompanyApril 23 at 4:41 AM | uk.finance.yahoo.comInnate Pharma S.A. (OTCMKTS:IPHYF) Sees Significant Increase in Short InterestApril 18, 2025 | americanbankingnews.comInnate Pharma S.A. (OTCMKTS:IPHYF) Sees Large Increase in Short InterestInnate Pharma S.A. (OTCMKTS:IPHYF - Get Free Report) was the recipient of a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 2,100 shares, a growth of 133.3% from the March 15th total of 900 shares. Currently, 0.0% of the company's stock are sold short. Based on an average trading volume of 100 shares, the days-to-cover ratio is presently 21.0 days.April 17, 2025 | marketbeat.comInnate Pharma (OTCMKTS:IPHYF) Trading Up 30.4% - Time to Buy?Innate Pharma (OTCMKTS:IPHYF) Shares Up 30.4% - What's Next?April 10, 2025 | marketbeat.comInnate Pharma SA: Innate Pharma Reports Full Year 2024 Financial Results and Business UpdateMarch 27, 2025 | finanznachrichten.deInnate Pharma S.A. (OTCMKTS:IPHYF) Short Interest UpdateInnate Pharma S.A. (OTCMKTS:IPHYF - Get Free Report) was the recipient of a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 1,600 shares, a growth of 220.0% from the January 31st total of 500 shares. Based on an average trading volume of 0 shares, the short-interest ratio is presently ∞ days.March 1, 2025 | marketbeat.comInnate Pharma Shares Rise After Breakthrough Therapy Designation for LacutamabFebruary 19, 2025 | marketwatch.com3 Promising Penny Stocks With Market Caps Under US$500MJanuary 31, 2025 | finance.yahoo.comShort Interest in Innate Pharma S.A. (OTCMKTS:IPHYF) Decreases By 94.0%Innate Pharma S.A. (OTCMKTS:IPHYF - Get Free Report) was the target of a significant decrease in short interest during the month of January. As of January 15th, there was short interest totalling 500 shares, a decrease of 94.0% from the December 31st total of 8,400 shares. Based on an average trading volume of 100 shares, the days-to-cover ratio is presently 5.0 days.January 28, 2025 | marketbeat.comInnate Pharma shares retain Buy rating on long-term strategyJanuary 17, 2025 | msn.comInnate Pharma S.A. (OTCMKTS:IPHYF) Short Interest Up 425.0% in DecemberInnate Pharma S.A. (OTCMKTS:IPHYF - Get Free Report) was the recipient of a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 8,400 shares, a growth of 425.0% from the November 30th total of 1,600 shares. Based on an average trading volume of 400 shares, the days-to-cover ratio is presently 21.0 days.December 26, 2024 | marketbeat.comPositive Outlook for Innate Pharma: Buy Rating Supported by Promising Lacutamab Phase 2 Results and Strong Financial PositionDecember 9, 2024 | markets.businessinsider.comInnate Pharma SA’s Innovations Spotlighted at ASH 2024December 3, 2024 | msn.comEvercore ISI Sticks to Its Buy Rating for Innate Pharma (IPHA)November 14, 2024 | markets.businessinsider.comInnate Pharma’s New CEO and Promising FDA FeedbackNovember 14, 2024 | markets.businessinsider.comInnate Pharma S.A. (OTCMKTS:IPHYF) Short Interest Up 22.4% in SeptemberInnate Pharma S.A. (OTCMKTS:IPHYF - Get Free Report) was the target of a large growth in short interest during the month of September. As of September 30th, there was short interest totalling 6,000 shares, a growth of 22.4% from the September 15th total of 4,900 shares. Based on an average daily volume of 600 shares, the days-to-cover ratio is currently 10.0 days.October 15, 2024 | marketbeat.comInnate Pharma Names Jonathan Dickinson CEO, Executive Board ChairmanOctober 14, 2024 | marketwatch.comInnate Pharma (NASDAQ:IPHA) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comInnate Pharma Rings the Closing BellOctober 4, 2024 | nasdaq.comFDA grants IND clearance for Innate Pharma’s solid tumour trialSeptember 23, 2024 | finance.yahoo.comKepler Capital Sticks to Its Hold Rating for Innate Pharma SA (IPHYF)September 11, 2024 | markets.businessinsider.comInnate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024September 9, 2024 | finance.yahoo.comInnate Pharma S.A. (OTCMKTS:IPHYF) Short Interest Down 8.8% in AugustInnate Pharma S.A. (OTCMKTS:IPHYF - Get Free Report) was the target of a large decline in short interest in the month of August. As of August 15th, there was short interest totalling 6,200 shares, a decline of 8.8% from the July 31st total of 6,800 shares. Based on an average trading volume of 500 shares, the days-to-cover ratio is presently 12.4 days.September 1, 2024 | marketbeat.comInnate Pharma S.A. (OTCMKTS:IPHYF) Short Interest Up 23.6% in JulyInnate Pharma S.A. (OTCMKTS:IPHYF - Get Free Report) was the recipient of a significant increase in short interest during the month of July. As of July 31st, there was short interest totalling 6,800 shares, an increase of 23.6% from the July 15th total of 5,500 shares. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days.August 17, 2024 | marketbeat.comInnate Pharma S.A. (OTCMKTS:IPHYF) Sees Large Growth in Short InterestInnate Pharma S.A. (OTCMKTS:IPHYF - Get Free Report) saw a significant growth in short interest in June. As of June 15th, there was short interest totalling 7,900 shares, a growth of 43.6% from the May 31st total of 5,500 shares. Based on an average trading volume of 1,100 shares, the short-interest ratio is presently 7.2 days.July 1, 2024 | marketbeat.comShort Interest in Innate Pharma S.A. (OTCMKTS:IPHYF) Declines By 6.8%Innate Pharma S.A. (OTCMKTS:IPHYF - Get Free Report) was the recipient of a significant decline in short interest in May. As of May 15th, there was short interest totalling 5,500 shares, a decline of 6.8% from the April 30th total of 5,900 shares. Based on an average trading volume of 2,200 shares, the short-interest ratio is currently 2.5 days.June 3, 2024 | marketbeat.comInnate Pharma Announces Its Participation in Upcoming Investor ConferencesMay 28, 2024 | finance.yahoo.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Curis (CRIS), Health Catalyst (HCAT) and Innate Pharma SA (OtherIPHYF)May 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Innate Pharma Amidst Promising Platforms and Strategic Growth PotentialApril 16, 2024 | markets.businessinsider.comInnate Pharma (OTCMKTS:IPHYF) Stock Price Up 2.7%Innate Pharma (OTCMKTS:IPHYF) Stock Price Up 2.7%April 3, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Innate Pharma SA (OtherIPHYF), Medios AG (OtherMEDOF) and Tecan Group AG (OtherTCHBF)March 23, 2024 | markets.businessinsider.comInnate Pharma Stock (OTC:IPHYF), Insider Trading ActivityFebruary 26, 2024 | benzinga.comInnate Pharma SA (IPHYF) Receives a Hold from Kepler CapitalFebruary 4, 2024 | markets.businessinsider.comInnate Pharma: Worth A Deeper LookJanuary 11, 2024 | seekingalpha.comAnalysts Conflicted on These Healthcare Names: Innate Pharma SA (OtherIPHYF), Amgen (AMGN) and Regeneron (REGN)January 6, 2024 | markets.businessinsider.comInnate Pharma Up 4% After FDA Lifts Partial Clinical Hold on LacutamabJanuary 4, 2024 | marketwatch.comShort Interest in Innate Pharma S.A. (OTCMKTS:IPHYF) Expands By 650.0%Innate Pharma S.A. (OTCMKTS:IPHYF - Get Free Report) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 4,500 shares, a growth of 650.0% from the November 30th total of 600 shares. Based on an average daily volume of 200 shares, the days-to-cover ratio is currently 22.5 days.December 28, 2023 | marketbeat.comInnate Pharma and Sanofi to license natural killer cell engagerDecember 19, 2023 | msn.comBuy Rating for Innate Pharma Backed by Promising Lacutamab Clinical Results and Regulatory ProspectsDecember 14, 2023 | markets.businessinsider.comInnate Pharma to Host Virtual KOL Event on LacutamabNovember 27, 2023 | finance.yahoo.comInnate Pharma Announces Conference Call for Third Quarter 2023 Business UpdateNovember 7, 2023 | finance.yahoo.comInnate Pharma Announces Its Participation to Upcoming Investor ConferencesOctober 27, 2023 | finance.yahoo.comInnate Pharma Announces Abstracts Selected for ESMO Congress 2023October 16, 2023 | finance.yahoo.comInnate Pharma Shares Fall Premarket on FDA Partial Study HoldOctober 5, 2023 | marketwatch.comRegulatory Hurdle For Innate Pharma's Blood Cancer StudiesOctober 5, 2023 | msn.comInnate Pharma Says FDA Places Partial Clinical Hold On Lacutamab IND; Stock Down 10%October 5, 2023 | markets.businessinsider.comInnate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023September 22, 2023 | finance.yahoo.comFirst Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple MyelomaJuly 11, 2023 | finance.yahoo.comNumber of Shares and Voting Rights of Innate Pharma as of July 1, 2023July 7, 2023 | finance.yahoo.com Get Innate Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IPHYF and its competitors with MarketBeat's FREE daily newsletter. Email Address IPHYF Media Mentions By Week IPHYF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IPHYF News Sentiment▼0.410.74▲Average Medical News Sentiment IPHYF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IPHYF Articles This Week▼20▲IPHYF Articles Average Week Get Innate Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IPHYF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ginkgo Bioworks News Cullinan Therapeutics News Relay Therapeutics News MeiraGTx News Tourmaline Bio News Autolus Therapeutics News Maze Therapeutics News Sana Biotechnology News Tectonic Therapeutic News REGENXBIO News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:IPHYF) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innate Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
